| Literature DB >> 34355525 |
Raquel Ortigão1, Jochen Weigt2, Ahmed Afifi2, Diogo Libânio1,3.
Abstract
BACKGROUND: Colonoscopy with polypectomy substantially reduces the risk of colorectal cancer (CRC) but interval cancers still account for 9% of all CRCs, some of which are due to incomplete resection. AIM: The aim of this review is to compare the outcomes of cold and hot endoscopic resection and provide technical tips and tricks for optimizing cold snare polypectomy.Entities:
Keywords: cold snare polypectomy; colonic polyps; colorectal cancer; endoscopic mucosal resection; sessile serrated lesion
Mesh:
Year: 2021 PMID: 34355525 PMCID: PMC8498395 DOI: 10.1002/ueg2.12130
Source DB: PubMed Journal: United European Gastroenterol J ISSN: 2050-6406 Impact factor: 4.623
FIGURE 1Granular laterally spreading tumor (LST‐G) removed by cold‐endoscopic mucosal resection (EMR) (courtesy of Dr. Dileep Mangira). (a), 30 mm LST‐G in the cecum; (b), Initial lift of the polyp; (c), Cold‐EMR ongoing; (d), Mucosectomy scar near the appendiceal orifice
FIGURE 2Cold snare polypectomy of a small adenoma. (a), Small adenoma, reaching into a sigmoid diverticula; (b), Positioning of the snare tip; (c), Applying pressure towards the colonic wall resulting in bending the snare to get more contact to the mucosa. This causes friction that ensures tissue collection into the snare while closing the snare; (d), Before transection of the mucosa you can make sure the snare position is optimal if normal mucosa can be seen inside the adenoma. Further retraction close to, or even into the beginning of the working channel while cutting ensures immediate specimen collection into a polyp trap
Summary of systematic reviews evaluating conventional (hot) endoscopic mucosal resection
| Studies | No. of LST | Size, mm | Complete endoscopic resection, | En bloc resection, | R0 resection, | Recurrence rate, | Perforation, | IPB, | PPB, | |
|---|---|---|---|---|---|---|---|---|---|---|
| 493/3405 (14.5%) | ||||||||||
| Belderbos T, 2014 | 33 | NA | >10 | NA | NA | NA |
| NA | NA | NA |
|
| ||||||||||
| Arezzo A, 2015 | 11 | 3161 | >20 | NA | 822/2358 (34.9%) | 166/458 (36.2%) | 384/3034 (12.7%) | 47/3161 (1.5%) | 89/3078 (2.9%) | |
| Russo P, 2019 | 49 | 3021 | >10 | NA (99.5%) | NA (37.7%) | NA (36.2%) | NA (12.6%) | NA (1.2%) | NA (9.6%) | |
| NA (7.7%) | NA | |||||||||
| Chandam S, 2020 | 11 | 1049 | NA | NA | 694/1188 (58.4%) | 226/297 (76.1%) | 64/254 (25.2%) | NA | 72/790 (9.1%) | NA |
| Zhao HJ, 2020 | 12 | 1906 | >10 | NA | 815/1906 (42.8%) | 92/128 (71.9%) | 233/1469 (15.9%) | 28/1568 (1.8%) | 68/1633 (4.2%) | |
Abbreviations: IPB, intra‐procedural bleeding; NA, Not available; PPB, post‐procedural bleeding.
Summary of studies evaluating cold snare polypectomy of polyps ≥10 mm
| Author, year | Patients | No. of polyps/SSL | >20 mm | Injection (+/−) | Median follow‐up (IQR), months | Recurrence rate | Adverse events per lesion | |||
|---|---|---|---|---|---|---|---|---|---|---|
| IPB | PPB | PPS | Perforation | |||||||
| Adenoma + SSL | ||||||||||
| Choksi N, 2015 | 15 | 15/0 | 11 (73.3%) | + | NA | NA | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) |
| Muniraj T, 2015 | 30 | 30/15 | 15 (50.0%) | + | NA | 5/27 (18.5%) | 0/30 (0%) | 0/30 | 0/30 | 0/30 |
| Piraka C, 2017 | 73 | 94/14 | 37 (39.4%) | + | 5.4 (1.1‐16.2) | 7/72 (9.7%) | 1/94 (0%) | 0/94 (0%) | 0/94 (0%) | 0/94 (0%) |
| Murakami T, 2019 | NA | 74/7 | NA | ‐ | NA | 4/74 (5.4%) | NA | 0/74 (0%) | NA | 0/74 (0%) |
| Mangira D, 2020 | 186 | 204/135 | 204 (100%) | + | 5.0 | 9/164 (5.5%) | 4/186 (2.2%) | 7/186 (3.8%) | 0/186 (0%) | 0/186 (0%) |
| SSL | ||||||||||
| Tutticci NJ, 2018 | 99 | 163 | 74 (45.4%) | + | 5.1 | 1/134 (0.7%) | 1/163 (0.6%) | 0/163 (0%) | NA | 0 (0%) |
| Rameshshankar R, 2018 | 10 | 29 | 9 (31.0%) | + | NA | 1/29 (3.4%) | 0/29 (0%) | 0/29 (0%) | 0/29 (0%) | 0/29 (0%) |
| McWhinney CD, 2020 | 312 | 566 | NA | + | 12.4 | 18/225 (8.0%) | NA | 4/223 (1.8%) | 0/223 (0%) | 0/223 (0%) |
| Kimoto Y, 2020 | 300 | 474 | 97 (20.5%) | ‐ | 7.0 | 0/384 (0%) | 8/300 (3%) | 0/300 (0%) | 0/300 (0%) | 0/300 (0%) |
| Yoshida N, 2020 | 100 | 160 | 0 (0%) | ‐ | 18.0 (12.0‐24.0) | 5/101 (5.0%) | 2/160 (1.3%) | 0/160 (0%) | 0/160 (0%) | 0/160 (0%) |
| Comparative studies | ||||||||||
| Tate DJ, 2018 | ||||||||||
| Piecemeal CSP | 34 | 41/41 | NA | ‐ | 6.0 (5.0‐7.0) | 0/15 (0.0%) | 0/41 (0%) | 0/41 (0%) | 0/41 (0%) | 0/41 (0%) |
| EMR | 20 | 20/20 | NA | ‐ | NA | 1/9 (11.1%) | NA | NA | NA | NA |
| Ket SN, 2019 | ||||||||||
| CSP | 241 | 346/206 | 0 (0%) | 243+ | NA | NA | 3/346 (0.9%) | 0/346 (0%) | 0/346 (0%) | 0/346 (0%) |
| HSP | 207 | 258/77 | 0 (0%) | 128+ | NA | NA | 15/258 (5.8%) | 4/258 (1.6%) | 2/258 (7.8%) | 0/258 (0%) |
| Hatem VA, 2020 | ||||||||||
| Piecemeal CSP | 121 | 156/156 | 156 (100%) | Both | 6.0 (4.0‐8.0) | 4/92 (4.3%) | 0/121 (0%) | 0/121 (0%) | NA | 0/121 (0%) |
| Piecemeal EMR | 353 | 406/406 | 406 (100%) | 6.0 (5.0‐9.0) | 14/307 (4.6%) | 18/353 (5.1%) | 5/353 (1.4%) | NA | 2/353 (0.6%) | |
Abbreviations: CSP, cold snare polypectomy; EMR, endoscopic mucosal resection; HSP, Hot snare polypectomy; IPB, intra‐procedural bleeding; NA, Not available; PPB, post‐procedural bleeding; PPS, Post‐polypectomy syndrome; SSL, sessile serrated lesions.
Per patient.
Thirteen visible lesion and five positive scar biopsies.